TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03807063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rivogenlecleucel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Given IV
Study: NCT01272414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 2-12 units in weekly 2u doses to effect

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Injection of 0.4cc 0.9% normal saline
Study: NCT03032614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
Study: NCT03835884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13503 Implant 10.6 Dose
Description: AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13503 Implant 21.2 Dose
Description: AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye
Study: NCT04325425

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin injection
Description: Cisplatin 100 mg/m2, IV infusion over 3 hours or Carboplatin AUC 5, IV infusion over 30 minutes on day 1 \[the dose of carboplatin will be determined for each cycle using the Calvert's formula (carboplatin dose (mg) = target AUC 5 x estimated glomerular filtration rate (eGFR, mL/min) + 25)\];~• Etoposide 100 mg/m² IV infusion over 1 hour on day 1,2 and 3
Study: NCT01584167

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
Description: Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
Study: NCT03835884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13503 42.4 Dose
Description: AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13503 63.6 Dose
Description: AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye
Study: NCT01175642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: Computer-based, therapist-lead cognitive remediation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation
Description: Computer-based, therapist-lead cognitive remediation
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Oxazepam

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil
Study: NCT01175642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FAST
Description: Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FAST
Description: Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
Study: NCT01669421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin (human)
Description: Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil
Study: NCT01669421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin (human)
Description: Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin (human)
Description: Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
Study: NCT03589391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOR measurement via device
Description: The epidural technique is totally performed in a sterile field without any harm to the patient. The LOR measurement is monitored via the bespoke device used during the epidural procedure.
Study: NCT04202510

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma and Cataract Surgery
Description: Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma and Cataract Surgery
Description: Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma and Cataract Surgery
Description: Patients requiring combined cataract and glaucoma surgery will be randomized to either iStent, iStent Inject or Hydrus (to lower intraocular pressure) combined with Phacoemulsification (to remove cataract and insert intraocular lens) Eye Surgery
Study: NCT04197063

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweetened beverage portion size limit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweetened beverage portion size limit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweetened beverage portion size limit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sweetened beverage portion size limit
Study: NCT04183855

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Generation UCAN supplementation
Description: carbohydrates - protein (Generation UCAN supplement, 250ml, 10% solution)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mirexus PhytoSpherix supplementation
Description: carbohydrates alone (Mirexus PhytoSpherix, 250ml, 10% solution)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: satiety ratings
Description: questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: satiety ratings
Description: questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: satiety ratings
Description: questionnaire on satiety ratings will be provided to participants 15, 30, 45 and 60 min after the drink (or no drink)
Study: NCT01994772

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted controlled temperature between 32.5 and 33.5°C
Description: Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted controlled temperature between 36.5 and 37.5°C
Description: Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Targeted controlled temperature between 36.5 and 37.5°C
Description: Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
Study: NCT01605227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: Tablets taken orally once-daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
Study: NCT00874406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tac + folfox4
Description: tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folfox4
Description: folfox4 will be done within 28 days after liver resection
Study: NCT01836796

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri
Description: 100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri
Description: 100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri DSM17938
Description: Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri DSM17938
Description: Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus Reuteri DSM17938
Description: Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
Study: NCT02362230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Icotinib 125 mg BID
Study: NCT05499338

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching program
Description: The stretching programme was to be performed at least 3 days/week (after training) for 12 weeks. These were static, active stretches of the muscles of the lower back, psoas iliacus, quadriceps, adductors, gluteus, hamstrings, and sural triceps. The final stretching position was that which generated a sensation of moderate-intense tightness in the muscles, but without exceeding the pain threshold. For each muscle group, the stretch was held for 60 seconds, divided into 3 repetitions of 20 seconds. Between each repetition, we did not return to the initial position but sought a new barrier to the stretch which would provoke the sensations described above. The total time dedicated to stretching was approximately 15 minutes per session.
Study: NCT00183378

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking Program
Description: The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Light Exposure Program
Description: The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined Education, Walking and Light Exposure Program
Description: The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Medical Care with Education
Description: The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
Study: NCT02501720

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: post burn flexion contractures release under tourniquet control
Description: post burn flexion contractures will be released under tourniquet control

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post burn flexion contractures release using tumescent solution
Description: post burn flexion contractures will be released using tumescent solution

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Contracture release and application of FTSG
Description: Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contracture release and application of FTSG
Description: Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
Study: NCT02418208

Intervention type: DIAGNOSTIC_TEST
Intervention: Performint EEG tests and BNA analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Performint EEG tests and BNA analysis
Study: NCT02510365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Functional collagen scaffold
Description: Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
Study: NCT00743028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-263
Description: Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil
Study: NCT01584167

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMCOOLS Flex.Pads
Description: Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
Study: NCT02718339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive counseling
Study: NCT04530370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recovered covid 19 patients plasma
Description: we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: recovered covid 19 patients plasma
Description: we transfused 150 ml of recovered covid 19 plasma to severely ill patients with confirmed covid 19 disease
Study: NCT02570581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Donepezil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Jelly with Clopidogrel
Study: NCT02399319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Symphyseal Plate
Description: A plate that spans across the symphysis to maintain reduction and stability.
Study: NCT01590797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg once daily for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo once daily for 24 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
Study: NCT04626648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pause with a sugar containing drink
Description: Three-minute long intraoperative pause, including a sugar-containing drink
Study: NCT01692366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:Capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:Capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:Capsule~Route of administration: oral
Study: NCT03352206

Intervention type: DRUG
Intervention: 2 drug dose - DA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine and albendazole (DA)

Intervention type: DRUG
Intervention: 3 drug dose - IDA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
Study: NCT00989014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47
Description: 0.5% Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47
Description: 0.18% Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47
Description: 0.07% Topical Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD07805/47 placebo
Description: Vehicle Topical Gel
Study: NCT02872467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon treatment
Description: 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
Study: NCT01132131

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delegation form
Description: The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delegation form
Description: The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.
Study: NCT05548829

Intervention type: BIOLOGICAL
Intervention: Disease severity
Description: Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.

Intervention type: BIOLOGICAL
Intervention: Disease severity
Description: Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.

Intervention type: BIOLOGICAL
Intervention: Disease severity
Description: Observational, based on biological outcome of Covid-19 infeection. Comparing pheripheral biomakers of Covid-19 patients admitted to hospital due to infection versus Covid-19 patients that recovered at home.
Study: NCT01013701

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate
Description: nasal steroid spray

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: nasal steroid vehicle without drug
Study: NCT04350788

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Survivorship Care Plan
Description: Participants visit the NCI prostate cancer website in addition to their standardized post-treatment survivorship care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Survivorship Care Plan
Description: In addition to their standardized post-treatment survivorship care, participants visit the prostate cancer education resources for couples (PERC) website that was based on scientific evidence and input from stakeholders including PC patients, partners, and cancer care providers. Participants learn about skills and knowledge about how to enhance their positive appraisals of symptoms and self-efficacy in symptom management through information and skills training, fostering healthy behaviors, and facilitating social support